Drug Profile
Research programme: neurodegenerative disorders therapeutics - PharmaNeuroBoost
Alternative Names: PNB 03; PNB 04Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PharmaNeuroBoost
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Belgium
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Belgium
- 09 Jan 2009 Preclinical trials in Alzheimer's disease in Belgium (unspecified route)